Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma.

Reiser H, Wang J, Chong L, Watkins WJ, Ray AS, Shibata R, Birkus G, Cihlar T, Wu S, Li B, Liu X, Henne IN, Wolfgang GH, Desai M, Rhodes GR, Fridland A, Lee WA, Plunkett W, Vail D, Thamm DH, Jeraj R, Tumas DB.

Clin Cancer Res. 2008 May 1;14(9):2824-32. doi: 10.1158/1078-0432.CCR-07-2061.

2.

Pharmacokinetics of oral zidovudine administered during labour: a preliminary study.

Mirochnick M, Rodman JH, Robbins BL, Fridland A, Gandía J, Hitti J, Bardeguez A, Rathore MH, Gonzalez Garcia A, Cababasay M, Samson P, Mofenson L, Bryson YJ, Dorenbaum A.

HIV Med. 2007 Oct;8(7):451-6.

3.

Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2'-deoxyadenosine triphosphate by ion-pairing LC/MS/MS.

Vela JE, Olson LY, Huang A, Fridland A, Ray AS.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 1;848(2):335-43. Epub 2006 Nov 13.

PMID:
17101307
4.

Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.

Ray AS, Myrick F, Vela JE, Olson LY, Eisenberg EJ, Borroto-Esodo K, Miller MD, Fridland A.

Antivir Ther. 2005;10(3):451-7.

PMID:
15918336
5.

Effective metabolism and long intracellular half life of the anti-hepatitis B agent adefovir in hepatic cells.

Ray AS, Vela JE, Olson L, Fridland A.

Biochem Pharmacol. 2004 Nov 1;68(9):1825-31.

PMID:
15450948
6.
7.

Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells.

Robbins BL, Wilcox CK, Fridland A, Rodman JH.

Pharmacotherapy. 2003 Jun;23(6):695-701.

PMID:
12820810
8.

A new sensitive cartridge-RIA method for determination of stavudine (D4T) triphosphate in human cells in vivo.

Tran TT, Robbins BL, Pinkerton FH Jr, Ferrua B, Grassi J, Fridland A.

Antiviral Res. 2003 Apr;58(2):125-9.

PMID:
12742572
9.

Cellular factors for resistance against antiretroviral agents.

Fridland A, Connelly MC, Robbins BL.

Antivir Ther. 2000 Sep;5(3):181-5. Review.

PMID:
11075937
10.
11.

Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The Pediatrics AIDS Clinical Trials Group.

Hughes WT, Shenep JL, Rodman JH, Fridland A, Willoughby R, Blanchard S, Purdue L, Coakley DF, Cundy KC, Culnane M, Zimmer B, Burchett S, Read JS.

Antimicrob Agents Chemother. 2000 Apr;44(4):1041-6.

12.

Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants.

Rodman JH, Flynn PM, Robbins B, Jimenez E, Bardeguez AD, Rodriguez JF, Blanchard S, Fridland A.

J Infect Dis. 1999 Dec;180(6):1844-50.

PMID:
10558940
13.

MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs.

Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A.

Nat Med. 1999 Sep;5(9):1048-51.

PMID:
10470083
15.
18.

Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication.

Pisarev VM, Lee SH, Connelly MC, Fridland A.

Mol Pharmacol. 1997 Jul;52(1):63-8.

PMID:
9224813
19.
20.

In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine.

Tanaka M, Srinivas RV, Ueno T, Kavlick MF, Hui FK, Fridland A, Driscoll JS, Mitsuya H.

Antimicrob Agents Chemother. 1997 Jun;41(6):1313-8.

21.

Quantitation of intracellular zidovudine phosphates by use of combined cartridge-radioimmunoassay methodology.

Robbins BL, Waibel BH, Fridland A.

Antimicrob Agents Chemother. 1996 Nov;40(11):2651-4.

22.

A systemic and cellular model for zidovudine plasma concentrations and intracellular phosphorylation in patients.

Rodman JH, Robbins B, Flynn PM, Fridland A.

J Infect Dis. 1996 Sep;174(3):490-9.

PMID:
8769605
23.

Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells.

Robbins BL, Greenhaw J, Connelly MC, Fridland A.

Antimicrob Agents Chemother. 1995 Oct;39(10):2304-8.

24.

Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.

Aduma P, Connelly MC, Srinivas RV, Fridland A.

Mol Pharmacol. 1995 Apr;47(4):816-22.

PMID:
7723743
26.
27.

Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells.

Robbins BL, Rodman J, McDonald C, Srinivas RV, Flynn PM, Fridland A.

Antimicrob Agents Chemother. 1994 Jan;38(1):115-21.

28.

Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis.

Balzarini J, Karlsson A, Wang L, Bohman C, Horská K, Votruba I, Fridland A, Van Aerschot A, Herdewijn P, De Clercq E.

J Biol Chem. 1993 Nov 25;268(33):24591-8.

29.

Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates.

Srinivas RV, Robbins BL, Connelly MC, Gong YF, Bischofberger N, Fridland A.

Antimicrob Agents Chemother. 1993 Oct;37(10):2247-50.

30.

Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells.

Connelly MC, Robbins BL, Fridland A.

Biochem Pharmacol. 1993 Sep 14;46(6):1053-7.

PMID:
8216348
31.
32.

Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine.

Ahluwalia G, Cooney DA, Hartman NR, Mitsuya H, Yarchoan R, Fridland A, Broder S, Johns DG.

Drug Metab Dispos. 1993 Mar-Apr;21(2):369-76.

PMID:
8097711
33.

Metabolic pathways for the activation of the antiviral agent 2',3'-dideoxyguanosine in human lymphoid cells.

Bondoc LL Jr, Ahluwalia G, Cooney DA, Hartman NR, Johns DG, Fridland A.

Mol Pharmacol. 1992 Sep;42(3):525-30.

PMID:
1328848
34.

Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine.

Hartman NR, Ahluwalia GS, Cooney DA, Mitsuya H, Kageyama S, Fridland A, Broder S, Johns DG.

Mol Pharmacol. 1991 Jul;40(1):118-24.

PMID:
1677450
35.

Modulation of metabolism and anti-HIV-1 activity of purine 2',3'-dideoxynucleosides by IMP dehydrogenase inhibitors.

Bondoc LL Jr, Robbins BL, Ahluwalia GS, Mitsuya H, Johns DG, Fridland A.

Adv Exp Med Biol. 1991;309A:49-53. No abstract available.

PMID:
1686351
36.

Metabolism of the carbocyclic nucleoside analogue carbovir, an inhibitor of human immunodeficiency virus, in human lymphoid cells.

Bondoc LL Jr, Shannon WM, Secrist JA 3rd, Vince R, Fridland A.

Biochemistry. 1990 Oct 23;29(42):9839-43.

PMID:
2271622
37.

Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2' ,3'-dideoxyguanosine.

Ahluwalia G, Cooney DA, Bondoc LL Jr, Currens MJ, Ford H, Johns DG, Mitsuya H, Fridland A.

Biochem Biophys Res Commun. 1990 Sep 28;171(3):1297-303. Erratum in: Biochem Biophys Res Commun 1990 Nov 30;173(1):481.

PMID:
1977386
39.

2'-Fluoro-2',3'-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2',3'-dideoxyadenosine.

Masood R, Ahluwalia GS, Cooney DA, Fridland A, Marquez VE, Driscoll JS, Hao Z, Mitsuya H, Perno CF, Broder S, et al.

Mol Pharmacol. 1990 Apr;37(4):590-6.

PMID:
2109183
40.

Metabolism in human leukocytes of anti-HIV dideoxypurine nucleosides.

Fridland A, Johnson MA, Cooney DA, Ahluwalia G, Marquez VE, Driscoll JS, Johns DG.

Ann N Y Acad Sci. 1990;616:205-16.

PMID:
2078020
41.

Comparative studies of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) with other pyrimidine nucleoside analogues.

Martin JC, Hitchcock MJ, Fridland A, Ghazzouli I, Kaul S, Dunkle LM, Sterzycki RZ, Mansuri MM.

Ann N Y Acad Sci. 1990;616:22-8. Review. No abstract available.

PMID:
1964029
42.

Growth and differentiation of a human T-cell leukemia cell line, CCRF-CEM, grafted in mice.

Houghton PJ, Mirro J Jr, Goorha RM, Raimondi SC, Fridland A, Houghton JA.

Cancer Res. 1989 Dec 15;49(24 Pt 1):7124-31.

43.

Regulation of purine deoxynucleoside phosphorylation by deoxycytidine kinase from human leukemic blast cells.

Sarup JC, Johnson MA, Verhoef V, Fridland A.

Biochem Pharmacol. 1989 Aug 15;38(16):2601-7.

PMID:
2548513
44.

Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells.

Johnson MA, Fridland A.

Mol Pharmacol. 1989 Aug;36(2):291-5.

PMID:
2549385
45.

Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells.

Johnson MA, Ahluwalia G, Connelly MC, Cooney DA, Broder S, Johns DG, Fridland A.

J Biol Chem. 1988 Oct 25;263(30):15354-7.

46.

Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro.

Hao Z, Cooney DA, Hartman NR, Perno CF, Fridland A, DeVico AL, Sarngadharan MG, Broder S, Johns DG.

Mol Pharmacol. 1988 Oct;34(4):431-5.

PMID:
2459590
47.

Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity.

Ahluwalia G, Cooney DA, Mitsuya H, Fridland A, Flora KP, Hao Z, Dalal M, Broder S, Johns DG.

Biochem Pharmacol. 1987 Nov 15;36(22):3797-800. No abstract available.

PMID:
3120727
48.
49.

Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity.

Cooney DA, Ahluwalia G, Mitsuya H, Fridland A, Johnson M, Hao Z, Dalal M, Balzarini J, Broder S, Johns DG.

Biochem Pharmacol. 1987 Jun 1;36(11):1765-8. No abstract available.

PMID:
3107569
50.

Mechanism for ara-CTP catabolism in human leukemic cells and effect of deaminase inhibitors on this process.

Fridland A, Verhoef V.

Semin Oncol. 1987 Jun;14(2 Suppl 1):262-8. No abstract available.

PMID:
3035721

Supplemental Content

Loading ...
Support Center